LOGO
LOGO

Zentalis: Targeting The Achilles' Heel Of Cyclin E1-Positive Platinum-resistant Ovarian Cancer

By Prabha Kurup   ✉  | Published:  | Google News Follow Us  | Join Us
cyclin 15062026 lt

Ovarian cancer is the second most common gynecologic cancer in the United States. However, its incidence has declined over the past several decades, likely due at least in part to more use of oral contraceptives and less use of menopausal hormone therapy, according to the American Cancer Society.

It is estimated that about 21,010 women will receive a new diagnosis of ovarian cancer and about 12,450 women will die from ovarian cancer this year.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.